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Abstract
The concept of avoidable mortality is intended to assessing health care system perfor-
mance. It is defined as premature deaths from selected disease groups that are consid-
ered either treatable through the timely and effective health care (amenable mortality), or 
preventable by public health interventions (preventable mortality). The purpose of study 
is to analyse the impact of four lists of causes of death created by researchers on ame-
nable mortality by country, sex and cause of death. Data on deaths were obtained from 
the WHO database for 20 European Union countries in 2014. We applied the method of 
direct standardisation using the European Standard Population, Spearman rank‐order 
correlation with statistical significance tests and confidence intervals. We found that the 
selection of diseases considered as amenable has not significantly impact on the cross‐
country comparison, but the weight of selected list of causes of death is significant at the 
national level. The concept has several limitations relating to selection of diseases and set-
ting age threshold over time, availability of health care resources, prevalence of diseases 
or variation of causes of death coding among countries. However, indicator of avoidable 
mortality offers a way of the evaluating effectiveness of health systems in maintaining 
and improving population health.
Keywords: avoidable mortality, amenable mortality, preventable mortality, health care 
system performance, health policy
1. Introduction
Health systems play an important role in improving population health what closely relates 
to assessing the effectiveness of health care systems as one of the main dimensions of health 
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system performance. Evaluating the effectiveness of health care systems requires pre‐defined 
objectives or the expected health outcomes that are usually measured by mortality and mor-
bidity. More specifically, length of life and quality of life are examined. These aggregate indi-
cators are not able to capture a clear impact of health care activities, especially quality of 
health care, on the health status of population. Therefore, more specific health outcome indi-
cators were developed, e.g. avoidable mortality by selected causes of death, infant mortality, 
prevalence or incidence of chronic diseases, avoidable hospitalisations, and others [1].
The question of how much health care contributes to the health of populations has been dis-
cussed for several decades. Although there is no indicator that would comprehensively reflect 
the performance of health care system, nevertheless, the suitable measurement seems to be 
a concept of avoidable mortality. The concept of avoidable mortality, as an indicator for the 
quality of health care services, defines premature deaths from selected disease groups that 
are considered either treatable through the medical services or preventable by influencing the 
population characteristics [2].
From the beginning 1970s, many researchers have tried to renew the list of causes of death 
considered as amenable by health care or preventable by health interventions (see Chapter 2). 
Unfortunately, many studies did not demonstrate the selection process of avoidable causes 
of death. This is a bias that raises a question if this concept is not influenced by subjective 
approach of the given researchers. Has this concept a potential to be applied both at national 
and international levels?
The main objective of this study is to analyse the impact of the four lists of causes of death on 
amenable mortality by country, sex and cause of death. By application of several methods of 
avoidable mortality, we have an ambition to point out possible fluctuations in their results and 
limitations of international comparison. These raise an appeal for confrontation of the scientific 
teams at national and international levels and for the development of comparative interna-
tional baseline. The most innovative part of the study is disputation whether the concept 
of avoidable mortality is reliable for international health systems comparison or not.
This chapter consists of six sections. Theoretical background of avoidable, amenable and pre-
ventable mortality, together with a literature review follows Section 1. Section 3 presents the 
description of the two recent modifications of the concept including cause of death struc-
ture. Section 4 deals with the empirical analyses of amenable mortality differentials across 
the European Union countries and describes the data and methods used. Section 5 provides 
a discussion about the potentials or limitations of the concept applied. The most meaningful 
conclusions are summarised at the end of the chapter.
2. Development of the concept of avoidable mortality
The concept of avoidable mortality was developed by Rutstein et al. [3]. They suggested that 
several diseases at certain ages should not occur in the presence of timely and effective health 
care. Additionally, they distinguished the diseases that should be amenable by the quality 
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of health care (e.g. diabetes mellitus treated with insulin) and those that were influenced by 
public health policy interventions (e.g. lung cancer prevented by smoking elimination). Their 
list of causes of death included more than 90 diseases considered as unnecessary, untimely 
causes of death and disabilities. Many research studies have tried to renew the list over time 
adjusting to the new medical and technological advances. In 1983, Charlton et al. [4] modified 
the number of conditions on 14 disease groups and excluded deaths that were not directly 
associated with health care, for example, deaths avoided by public health prevention pro-
grams comprising alcohol or tobacco consumption. At the end of the 1980s, the concept was 
proceeded by several researchers [5, 6], but the highest progress was achieved by Holland 
[7] who created a European Community atlas of avoidable mortality modifying the previous 
authors. As for a main benefit of the atlas, strict distinguishing between types of health care 
services on primary care, hospital care and collective health services was interpreted. In 1993 
and 1997, second and third editions of atlas adjusting the number of diseases were created 
by Holland [8, 9] again, and further developed by other authors [10–13]. In spite of chang-
ing list of causes of death, age limit was mostly set at 65 years, what was about the average 
life expectancy in developed countries in those years. According to experts, above this age, 
the treatment of selected diseases is less obvious and appearance of co‐morbidities becomes 
problematic.
In 2001, Tobias and Jackson [14] derived the weights for primary, secondary and tertiary 
health interventions on the basis of a medical expert consensus. For example, avoidability of 
deaths from HIV/AIDS was distributed according to the primary level with weights 0.9, the 
secondary level with weights 0.05 and the tertiary level weighted 0.05. To compare, deaths 
from hypertensive disease were avoidable first by secondary interventions with weights 
0.65, second by tertiary interventions with weights 0.3 and finally by primary interventions 
weighted 0.05. Unfortunately, all above‐mentioned proposals of the concept of avoidable 
mortality did not consider the availability of health care resources such as current technology, 
medical skills, human resources or health expenditures in a certain country.
A new perspective view on the concept was presented by Nolte and McKee [15] in 2004. 
They conducted a broad review of randomised controlled trials providing the evidence of 
impact of health services on survival taking into account advances in medical knowledge 
and technology across the European Union countries during the 1980s and 1990s. The pre-
vious lists of causes of death created by Mackenbach et al. [6] or Charlton et al. [4] were 
changed on 34 groups of diseases comprising amenable, preventable conditions and isch-
aemic heart disease separately. Ischaemic heart disease was represented as a separate group 
because the highest number of these deaths could bias the influence of health services on 
other diseases. Additionally, the concept considers only 50% of deaths from ischaemic heart 
disease. Another reason was that ischaemic heart disease could be understood partially as 
amenable but also as preventable cause of death. Some causes of death were added to the 
list and some were removed. For example, malignant neoplasm of prostate was not included 
because an available time trends analysis of cancer mortality showed a small decrease of 
mortality from prostate cancer, together with the uncertain impact of screening. On the 
other hand, they included colorectal cancer on the basis of randomised controlled trials 
providing that curative resection had a significant impact on survival. Establishing an upper 
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age limit varied across diseases. The vast majority were set at 75 years, with the exception 
of diabetes mellitus (lower than 50 years), some infectious and respiratory diseases (lower 
than 15 years), malignant neoplasm of cervix uteri and body uterus, as well as leukaemia 
(lower than 45 years). This was the result of studies that reported substantial improvements 
in mortality from these diseases relating to advances in treatment before mentioned age 
limits.
The concept was further renewed analysing European and non‐European countries due to 
the works by Nolte and McKee [16] in 2008 and Tobias and Yeh [17] in 2009. Nolte and 
McKee closely followed up their last list of causes of death from 2004, while Tobias and Yeh 
discussed some new inclusion and exclusion criteria. Infectious diseases varied significantly. 
While Nolte and McKee concentrated on infectious disease of children before the age of 
15, Tobias and Yeh focused on selective invasive bacterial infections such as scarlet fever, 
meningococcal infection, etc. They argued that early detection and treatment by antibiotic 
therapy decrease mortality substantially. Moreover, only half of the mortality from cerebro-
vascular diseases, ischaemic heart disease and diabetes mellitus are considered as amenable 
by appropriate health care according to Tobias and Yeh, because the second half can be 
preventable by health behaviours (e.g. healthy lifestyle, obesity prevention). The authors 
of mentioned lists of diseases have different opinions on setting age limit for some causes 
of death; however, there are more similarities than discrepancies between these two lists of 
diseases (Table 1).
Cause of death Nolte and McKee [16] ICD‐10 Tobias and Yeh [17] ICD‐10
Infectious disease
Tuberculosis A15–A19, B90 A15–A19, B90
Selected invasive infections:
Intestinal infectious diseases A00–A09 (age 0–14) Non‐classified
Whooping cough A37 (age 0–14) Non‐classified
Measles B05 (age 1–14) Non‐classified
Tetanus and Diphtheria A35–A36 Non‐classified
Sepsis A40–A41 A40–A41
Scarlet fever Non‐classified A38
Meningococcal infection Non‐classified A39
Acute poliomyelitis A80 Non‐classified
Influenza J10–J11 Non‐classified
Pneumonia J12–J18 J13–J15, J18
Erysipelas Non‐classified A46
Legionnaires disease Non‐classified A481
Malaria Non‐classified B50–B54
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Cause of death Nolte and McKee [16] ICD‐10 Tobias and Yeh [17] ICD‐10
Meningitis Non‐classified G00, G03
Cellulitis Non‐classified L03
Neoplasms
Colorectal cancer C18–C21 C18–C21
Malignant neoplasms of skin C44 C43–C44
Breast cancer C50 C50
Cervical cancer C53 C53
Uterine cancer C54–C55 (age 0–44) C54–C55
Testis cancer C62 Non‐classified
Bladder cancer Non‐classified C67
Thyroid cancer Non‐classified C73
Hodgkin's disease C81 C81
Leukaemia C91–C95 (age 0–44) C91–C95 (age 0–44)
Benign neoplasms Non‐classified D10–D36
Diabetes mellitus (type 2) E10–E14 (age 0–49) E10–E14 (50% of deaths)
Ischaemic heart disease I20–I25 (50% of deaths) I20–I25 (50% of deaths)
Other circulatory disease
Rheumatic and other valvular heart 
disease
I05–I09 I01–I09
Hypertensive heart disease I10–I13, I15 I11
Cerebrovascular diseases I60–I69 I60–I69 (50% of deaths)
Respiratory diseases (excl. pneumonia, 
influenza) (age 1–14)
J00–J09, J20–J99 Non‐classified
Chronic obstructive pulmonary disease Non‐classified J40–J44 (age >45)
Asthma Non‐classified J45–J46 (age 0–44)
Surgical conditions
Peptic ulcer disease K25–K27 K25–K28
Appendicitis K35–K38 K35–K38
Hernia K40–K46 K40–K46
Cholelithiasis, cholecystitis K80–K81 K80–K83
Pancreatitis Non‐classified K85–K86
Postcholecystectomy syndrome Non‐classified K915
Nephritis and nephrosis N00–N07, N17–N19, N25–N27 I12–I13, N00–N09,N17–N19
Obstructive uropathy and prostatic 
hyperplasia
N40 N13, N20–N21, N35, N40, N991
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The second latest study ‘Amenable mortality in the European Union: toward better indica-
tors for the effectiveness of health systems’ (AMIEHS) [18] in 2011 introduced an empirical 
evidence of selecting diseases into the lists of causes of death. Finally, a recent project has 
referred to the avoidable mortality indicators defined according to the Eurostat ‘Satellite List’ 
Task Force [19] in 2013. A common objective of these studies is to reach a consensus by coun-
tries of the European Community about the definition and selection of causes of avoidable 
deaths. Both studies are further described in Section 3 more specifically for the purposes of 
our analysis.
3. Conceptual methods
3.1. AMIEHS project from 2011
The AMIEHS project (Amenable mortality in the European Union: toward better indicators 
for the effectiveness of health systems) was introduced in 2011 by researchers represent-
ing prestigious universities from seven EU countries: the Netherland, the United Kingdom, 
Sweden, France, Estonia, Germany and Spain.
The main aim of this project is to develop an agreed definition of amenable mortality for Europe 
and introduce a renewed way of selecting diseases into the lists of causes of death that are 
amenable by health care which can be used in assessing effectiveness of health systems. They 
applied strict selection process of diseases based on the consecutively conducted analyses. 
First, they identified 54 diseases for which mortality declined more than 30% between 
1979 and 2000, and for which the number of deaths in 2000 exceeded 100 in England or 
Wales. These countries were selected because they disposed the most consistent data over 
Cause of death Nolte and McKee [16] ICD‐10 Tobias and Yeh [17] ICD‐10
Misadventures to patients during 
surgical and medical care
Y60–Y69, Y83–Y84 Non‐classified
Maternal, congenital and perinatal conditions
Maternal deaths O00–O99 Non‐classified
Perinatal deaths, all causes (excl. 
stillbirths)
P00–P96 H311, P00, P03–P95
Congenital malformations Q20–Q28 Q00–Q99
Other conditions
Thyroid disorders E00–E07 E00–E07
Epilepsy G40–G41 G40–G41
Note: Age group used for calculation is 0–74 except if otherwise mentioned.
Source: Own processing based on Nolte and McKee [16] and Tobias and Yeh [17].
Table 1. Causes of death selected in the amenable mortality list of Nolte and McKee [16] and Tobias and Yeh [17].
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this period. Second, they conducted a systematic review of the literature in order to iden-
tify health care interventions, which were introduced in 1970–2000 and shown as effective in 
reducing mortality.
Evidence of effectiveness of interventions was evaluated on a four‐point scale. The highest 
grade was denoted as (4)—evidence from systematic reviews or meta‐analysis; (3)—ran-
domised controlled trial; (2)—observational studies; and (1)—consensus statements or expert 
opinions. Grade of evidence of the decrease in mortality of 30% or more due to effective 
impact of health care interventions was evaluated on a three‐point scale: (3)—evidence from 
population‐based registers (e.g. cancer registries) of reduction in mortality; (2)—published 
studies describing decline in mortality at population level where investigation has identified 
health care interventions as the most likely explanation; and (1)—published studies describ-
ing decline in mortality at population level where investigation has identified health care 
interventions as one among several explanations.
However, the strength of the evidence was variable, only few interventions had the high-
est grade and many interventions were supported by evidence from observational studies 
only. The highest levels of evidence were observed, for example, in HIV‐related mortality that 
between 1996 and 1998 fell by 60% in the United States due to the key intervention attribut-
able to the azidothymidine and zidovudine applied in the late 1980s. Evidence of patient‐level 
studies reflected a major influence of treatment on mortality during the early 1990s. The result 
of these efforts was the list of 16 causes of death for which a review of the literature indicated 
the appropriate level of evidence of treatment (Table 2). Those causes of death, in which suc-
cessful health care interventions were introduced before 1970, e.g. infectious diseases treated 
successfully with antibiotics or diabetes by insulin were eliminated from the list of amenable 
causes of death.
Cause of death AMIEHS (2011) ICD‐10 EUROSTAT (2013) ICD‐10
Infectious disease
Tuberculosis Non‐classified A15–A19, B90
Selected invasive bacterial and 
protozoal infections
Non‐classified A38–A41, A46, A481,B50–B54, G00, 
G03, J02, L03
Hepatitis C Non‐classified B171, B182
HIV B20–B24 B20–B24 (all ages)
Neoplasms
Colorectal cancer C18–C21 C18–C21
Malignant neoplasms of skin Non‐classified C43
Breast cancer C50 C50
Cervical cancer C53 C53
Testis cancer C62 Non‐classified
Bladder cancer Non‐classified C67
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Cause of death AMIEHS (2011) ICD‐10 EUROSTAT (2013) ICD‐10
Thyroid cancer Non‐classified C73
Hodgkin's disease C81 C81
Leukaemia C91 C91, C920 (age 0–44)
Benign neoplasms Non‐classified D10–D36
Diabetes mellitus (type 2) Non‐classified E10–E14 (age 0–49)
Ischaemic heart disease I20–I25 I20–I25
Other circulatory disease
Rheumatic and other valvular heart 
disease
I00–I09 I01–I09
Hypertensive heart disease I10–I13 I10–I15
Heart failure I50–I51 Non‐classified
Cerebrovascular diseases I60–I69 I60–I69
Respiratory diseases
Influenza (including swine flu) Non‐classified J09–J11
Pneumonia Non‐classified J12–J18
Asthma Non‐classified J45–J46
Surgical conditions
Gastric and duodenal ulcer K25–K26 K25–K28
Acute abdomen, appendicitis, 
intestinal obstruction, cholecystitis/
lithiasis, pancreatitis, hernia
Non‐classified K35–K38, K40–K46, K80–K83, K85, 
K861–K869, K915
Nephritis and nephrosis N17–N19 N00–N07, N17–N19, N25–N27
Obstructive uropathy and prostatic 
hyperplasia
Non‐classified N13, N20–N21, N35, N40, N991
Congenital and perinatal conditions
Complications of perinatal period P00–P96 P00–P96, A33 (all ages)
Congenital malformations, 
deformations and chromosomal 
anomalies
Q20–Q24 Q00–99
Other condition
Epilepsy and status epilepticus Non‐classified G40–G41
Misadventures to patients during 
surgical and medical care
Non‐classified Y60–Y69, Y83–Y84 (all ages)
Note: Age group used for calculation is 0–74 except if otherwise mentioned.
Source: Own processing based on AMIEHS and EUROSTAT's proposals.
Table 2. Comparison of the AMIEHS and the EUROSTAT's list of causes of death considered amenable to health care.
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For each selected cause of death, mortality trends were analysed using regression analyses 
to specify points in time at which the mortality trend changed significantly. They applied 
age limit 75 years of age. The trend analyses examined the validation of amenable mortality 
indicators. The results were also validated by a Delphi method where experts assessed the 
likelihood that variations in mortality from the pre‐selected conditions reflect variations in 
the effectiveness of health care. Surprisingly, the experts reached consensus on only three 
diseases: colorectal cancer, cervical cancer and cerebrovascular disease. These results raise 
doubts about availability of amenable mortality as a valid indicator of effectiveness of health 
systems in international comparisons. Their analyses showed that although the treatment for 
surgical emergencies has been known for decades, mortality has continued to decline, reflect-
ing a combination of some other factors, for example, increasing skill in treatment or better 
treatment of complications. However, the AMIEHS project has proved that amenable mortal-
ity partially reflects the impact of health care innovations but must be interpreted with other 
analyses examining such as quality of health care utilisation or access to health care resources.
Finally, an electronic atlas of amenable mortality was prepared that provides trends of stan-
dardised mortality rates in European countries according to the list of causes of death over 
the period 2001–2009 [20].
3.2. Eurostat task force on satellite lists of causes of death from 2013
At the request of European member states, policy makers and experts in the field of public 
health to enhance information on specific groups of causes of death, Eurostat established a 
Task Force for revising a Satellite Lists of causes of death information on major public health 
issues. These public health themes also include the two concepts of avoidable mortality: ame-
nable and preventable deaths. This satellite list should serve as a comprehensive information 
platform on at‐risk groups of population in the European countries. The Task Force had some 
meetings were decided to consider the list of avoidable causes of death based on the three 
publications by the Office for National Statistics of the United Kingdom.
First of them, the consultation document [21] from February 2011 consists of the literature 
review, comparative analyses of existing selections of causes and consultations with experts 
to agree or disagree with the proposed disease classification. A public consultation was run-
ning between February and April 2011. The second one was the ‘Responses to the public 
consultation on definitions of avoidable mortality’ [22] from August 2011. This document 
contains 20 responses to the consultation document from various medical experts on five key 
questions of revising the definition of avoidable mortality concept. These questions related to 
the proposed causes of death to be included in amenable or preventable mortality, agreement 
or disagreement with the proposals on age limits, and how they would change them. Third, 
the final definition of avoidable mortality was presented in a document ‘Definition of avoid-
able mortality’ [23] at the end of 2011.
The Members of Eurostat’s Working Group of Public Health Statistics approved the list of 
diseases and age groups proposed by the Office for National Statistics of the United Kingdom. 
Hence, the Eurostat ‘satellite lists’ Task Force tested this proposed selection of causes of death 
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by Delphi method; unfortunately, those results are not disseminated. The final EUROSTAT 
Satellite List defining causes of death considered as amenable or preventable is available at 
Eurostat web page [24]. We present the list of causes considered to be amenable in Table 2.
As one should notice, the development of concept of avoidable mortality has been consid-
erably influenced by the evidence from clinical research studies or consultation that has 
confirmed the impact of health care or public health interventions on declining mortality. 
However, a considered time period has played an important role in creating the unique list of 
selected diseases, because medical knowledge and technology have advanced over time what 
subsequently has an impact on inclusion or exclusion criteria by which a list of amenable or 
preventable causes of death is made. Therefore, the lists of causes of death amenable to health 
care need to be regularly updated in relation to current medical practice.
3.3. Office for national statistics in England
Although avoidable mortality has been investigated for the last four decades, there is still 
small consensus among researchers about how to define it. Last precise definitions of the con-
cept are presented by the Office for National Statistics in England [25]. Following definitions 
were developed through an iterative public consultation running in 2015.
3.3.1. Avoidable mortality
Avoidable deaths are all those defined as preventable, amenable (treatable) or both, where 
each death is counted only once; where a cause of death is both preventable and amenable, 
all deaths from that cause are counted in both categories when they are presented separately.
3.3.2. Amenable mortality
A death is amenable (treatable) if, in the light of medical knowledge and technology at the 
time of death, all or most deaths from that cause (subject to age limits if appropriate) could be 
avoided through good quality healthcare.
3.3.3. Preventable mortality
A death is preventable if, in the light of understanding of the determinants of health at time 
of death, all or most deaths from that cause (subject to age limits if appropriate) could be 
avoided by public health interventions in the broadest sense.
4. Analysis
In our analysis, we examine the impact of the lists of causes of death on amenable mortality 
by country, sex and cause of death. We compare the results of amenable mortality across the 
European Union (EU) countries calculated by the four lists of causes of death. Then, we are 
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interested whether the two latest developed lists (AMIEHS and EUROSTAT) have a statisti-
cally significant impact on amenable mortality in Slovakia identifying the most influential 
group of diseases.
4.1. Data and methods
This section introduces what kind of dataset and methods are applied on the estimation of 
age‐standardised amenable death rates when comparing the EU countries. It also includes 
information how significances of the results have been tested.
4.1.1. Data
Our main source of mortality data is the raw data files of the WHO Mortality Database, where 
the causes of death are coded using the ICD‐10 classification at fourth digit level by five‐year 
age groups. We conduct analysis on data from 2014, as it is the latest available time point. The 
data in the required structure for calculation of amenable mortality are available for 19 EU 
countries, while other EU countries do not meet the requirements of this analysis due to data 
incompleteness at some age groups. We select causes of death that are proposed by the Nolte 
and McKee, Tobias and Yeh, AMIEHS, EUROSTAT's list regardless to the age limit. Statistical 
database of the United Nations Economic Commission for Europe is the main source for data 
on mid‐year population at the age groups. For comparison of mortality across EU countries, 
we adopt the European standard population by age groups according to the last revision in 
2012, proceeding in 2013 [26].
4.1.2. Methods
We estimate age‐standardised amenable death rates per 100,000 population by the direct 
method of standardisation to overcome an effect from variations in the age and sex structure 
across countries. First, the age and sex‐specific death rates for the given causes of death are 
calculated in each examined country. Second, the age‐specific death rate and the European 
standard population for each age interval are multiplied, and these results are summed. 
Finally, this sum is divided by the total standard population, in our case 100,000, to calculate 
the age‐standardised death rate [27].
Two directly standardised rates calculated by the same standard population can be com-
pared, and differences tested for statistical significance. To determine an association of coun-
tries’ rank order according to the standardised death rates between the lists each other, we 
run a Spearman rank‐order correlation with statistical significance tests. Probability values 
are computed from a t‐distribution with N‐2 degrees of freedom.
To find out whether age‐standardised rates of amenable mortality based on the two lists are 
significantly different by sex and causes of death in Slovakia, we calculate 95% confidence 
intervals that are equivalent to statistical tests. As a general rule, a difference is statistically 
significance if a confidence interval around rate non‐overlap with the interval around another 
[28]. Calculations are made using statistical software R Studio.
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4.2. Between‐list differences of amenable mortality across the European Union countries
This section compares the results of age standardised death rates across the European Union 
countries based on data from 2014 using the four evolutionarily most recent selections of ame-
nable diagnoses. We tested the six null hypothesis statements (H0) against the six alternative 
hypotheses (H1):
• H0: There is no association between the standardised death rates calculated by Nolte and 
McKee's list and the standardised death rates calculated by Tobias and Yeh's list.
• H1: There is an association between the standardised death rates calculated by Nolte and 
McKee's list and the standardised death rates calculated by Tobias and Yeh's list.
• H0: There is no association between the standardised death rates calculated by Nolte and 
McKee's list and the standardised death rates calculated by AMIEHS's list.
• H1: There is an association between the standardised death rates calculated by Nolte and 
McKee's list and the standardised death rates calculated by AMIEHS's list.
• H0: There is no association between the standardised death rates calculated by Nolte and 
McKee's list and the standardised death rates calculated by EUROSTAT's list.
• H1: There is an association between the standardised death rates calculated by Nolte and 
McKee's list and the standardised death rates calculated by EUROSTAT's list.
• H0: There is no association between the standardised death rates calculated by Tobias and 
Yeh's list and the standardised death rates calculated by AMIEHS's list.
• H1: There is an association between the standardised death rates calculated by Tobias and 
Yeh's list and the standardised death rates calculated by AMIEHS's list.
• H0: There is no association between the standardised death rates calculated by Tobias and 
Yeh's list and the standardised death rates calculated by EUROSTAT's list.
• H1: There is an association between the standardised death rates calculated by Tobias and 
Yeh's list and the standardised death rates calculated by EUROSTAT's list.
• H0: There is no association between the standardised death rates calculated by AMIEHS's 
list and the standardised death rates calculated by EUROSTAT's list.
• H1: There is an association between the standardised death rates calculated by AMIEHS's 
list and the standardised death rates calculated by EUROSTAT's list.
Table 3 reports the Spearman's rank correlation matrix with a statistical significance of corre-
lation coefficients. All calculated probability values achieved a value of p < 0.001, what means 
that we can reject the null hypothesis. In other words, despite any concept of amenable mor-
tality applied, there is a significant very strong positive correlation of the standardised death 
rates. Generally, the Spearman's correlation test calculated on standardised death rates of 
amenable causes using the Nolte and McKee, Tobias and Yeh, AMIEHS or EUROSTAT's con-
cepts, shows that the rank order of countries does not change significantly.
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These results are depicted in Figure 1. The four lists provide different levels of amenable 
mortality rates for countries; however, the rank order of countries is very similar. In 2014, 
France accounted for the best results of amenable mortality obtained from the all examined 
lists, ranged from 61 to 79 deaths per 100,000 population. On the other hand, the worst rate 
was recorded in Romania, 275 per 100,000 calculated by Nolte and McKee's list, as well as an 
average of 309 deaths per 100,000 in Latvia estimated by three remaining lists.
Generally, the standardised death rates for EU‐19 calculated by Eurostat's list were 40.5% 
higher than rates calculated by Nolte and McKee's list. On the other hand, the rates calculated 
according to the lists of Tobias and Yeh or AMIEHS were nearly the same, 161 per 100,000, 162 
per 100,000, respectively. Using the Nolte and McKee's list, the amenable mortality rates for 
EU‐19 reached the lowest value, 128 deaths per 100,000 population. The standard deviations 
(not shown in this document) expressing the rate of variability of standardised amenable death 
rates between lists, gained the highest values in Eastern European countries (Latvia, Lithuania, 
Slovakia, Hungary, Romania, the Czech Republic, Poland), along with Denmark, Estonia, the 
United Kingdom, Croatia, had still standard deviations above the average of EU‐19. A gradual 
decline of the variation in amenable mortality rates, below an average of EU‐19, was demon-
strated in the Netherlands, Germany, Luxembourg, Malta, Sweden, Finland, Spain and France.
Observed between‐list differences of the level of standardised amenable death rates in the EU 
countries are due to discrepancies in selected diseases and age limits. However, when assess-
ing the effectiveness of health systems in examined countries, it has not changed significantly.
4.3. The impact of AMIEHS and EUROSTAT's list on amenable mortality by cause of 
death in Slovakia
The analysis examines whether age‐standardised rates of amenable mortality based on 
AMIEHS or EUROSTAT's list are significantly different by sex and causes of death in Slovakia. 
We apply both lists on data for 2014.
sdr_NOLTE & McKEE sdr_TOBIAS & YEH sdr_AMIEHS sdr_EUROSTAT
sdr_NOLTE & McKEE 1.0000000 0.9403509 0.9877193 0.9807018
p‐value 8.377e‐06 4.836e‐06 8.402e‐06 8.267e‐06
sdr_TOBIAS & YEH 0.9403509 1.0000000 0.9333333 0.9456140
p‐value 4.836e‐06 8.377e‐06 3.74e‐06 5.562e‐06
sdr_AMIEHS 0.9877193 0.9333333 1.0000000 0.9894737
p‐value 8.402e‐06 3.74e‐06 8.377e‐06 8.418e‐06
sdr_EUROSTAT 0.9807018 0.9456140 0.9894737 1.0000000
p‐value 8.267e‐06 5.562e‐06 8.418e‐06 8.377e‐06
Note: Probability values computed from a t distribution with N‐2 degrees of freedom. N = 19.
Source: Own calculation using R Studio.
Table 3. Spearman's rank correlation matrix with p‐values calculated for standardised death rates (sdr) by country based 
on the four lists of amenable causes, 2014.
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In Slovakia, there was a considerable increase in the number of deaths considered ame-
nable, from 9325 by the AMIEHS's list to 10,451 under the EUROSTAT's list. Of the addi-
tional 1126 deaths, 753 were for men and 373 for women. The increase occurred in all age 
groups, mostly after 55 years of age, and also not negligibly in the children aged from 0 to 
4 years. The majority of the increase was due to the inclusion of respiratory diseases in the 
EUROSTAT's list that contributed 585 deaths of the 1126 deaths. The increase in the number 
of amenable deaths revealed that the total amenable mortality rates, as well as the rates for 
men and women, calculated by EUROSTAT's list were significantly higher (by 14.2% for men 
and 11.3% for women) than the rates under the AMIEHS's list. Generally, a difference is 
statistically significance if a confidence interval around rate non‐overlap with the interval 
around another (Table 4).
Table 5 reflects the age‐standardised amenable mortality rates, based on the AMIEHS and 
EUROSTAT's list (with 95% confidence intervals) by broad cause group in Slovakia, 2014.
Besides the inclusion of respiratory diseases in the EUROSTAT's list, the increases in the num-
ber of deaths were also due to the inclusions of epilepsy contributing 96 deaths, diabetes with 37 
deaths and misadventures to patients during surgical and medical care adding 15 deaths. Thus, 
Figure 1. Amenable mortality across the European Union countries by the four lists of causes of death, 2014. Source: Own 
calculation based on the data from WHO mortality database.
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AMIEHS's list EUROSTAT's list
Sex Number of 
deaths
Rate per 
100,000 
population
Lower 95% 
CI
Upper 95% 
CI
Number of 
deaths
Rate per 
100,000 
population
Lower 95% 
CI
Upper 95% 
CI
Men 5730 290.3 282.6 298.0 6483 331.4 323.9 338.9
Women 3595 150.1 145.2 155.0 3968 167 162.3 171.7
Total 9325 212.6 208.2 217.0 10,451 240.1 235.9 244.3
Note: CI, confidence interval.
Source: Own calculation based on the data from WHO mortality database.
Table 4. Number of deaths and standardised amenable death rates based on AMIEHS or EUROSTAT's list in Slovakia, 
2014.
AMIEHS's list EUROSTAT's list
Cause group Number  
of deaths
Rate per 
100,000
Lower  
95% CI
Upper  
95% CI
Number  
of deaths
Rate per 
100,000
Lower  
95% CI
Upper 
95% CI
All amenable  
causes
9325 212.6 208.2 217.0 10,451 240.1 235.9 244.3
Infectious disease 1 0.02 0.0 0.06 159 3.5 3.0 4.0
Neoplasms 2020 44.6 42.6 46.6 2,324 52.2 50.2 54.2
Diabetes mellitus  
(type 2)
nc nc nc nc 37 1.1 0.9 1.3
Ischaemic heart  
disease
4184 96.6 93.6 99.6 4184 96.6 93.6 99.6
Other circulatory  
disease
2650 61.3 58.9 63.7 2276 53.5 51.5 55.5
Respiratory  
diseases
nc nc nc nc 585 13.4 12.4 14.4
Surgical conditions 275 6.3 5.6 7.0 465 10.5 9.6 11.4
Congenital and  
perinatal conditions
195 3.7 3.2 4.2 310 5.7 5.1 6.3
Epilepsy and status  
epilepticus
nc nc nc nc 96 2.0 1.6 2.4
Misadventures to  
patients during  
surgical and  
medical care
nc nc nc nc 15 0.3 0.1 0.5
Note: nc, non‐classified.
Source: Own calculation based on the data from WHO mortality database.
Table 5. Standardised amenable mortality rates based on the AMIEHS and EUROSTAT's list (with 95% confidence 
intervals) by broad cause group in Slovakia, 2014.
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additional causes of death included in the EUROSTAT's list accounted for 12.1%. A largest share 
in both lists is presented by ischaemic heart disease representing 44.9% under the AMIEHS's 
list and 40% in the EUROSTAT's list. However, standardised death rate of ischaemic heart dis-
ease has not changed when comparing the two lists. The other circulatory disease reported the 
statistically significant decrease of standardised death rates by 14.1% in the EUROSTAT's list 
contrary to the AMIEHS's list that was due to the exclusion of heart failure from the group. 
However, heart failure represented a substantial cause accounted for 14.1% in the group of 
other circulatory disease under the AMIEHS's list. In spite of the fact that infectious disease 
reflected the lowest numbers of deaths in the both lists, they recorded the largest statistically 
significant increase under the EUROSTAT's list because of the additional causes of death (tuber-
culosis, hepatitis C, selected invasive bacterial and protozoal infections) to the HIV contained in 
the AMIEHS's list. Moreover, in the HIV cause group, there was the extension of the age limit 
on the all age groups, whereas the age limit 0–74 years was included in the AMIEHS's list. In 
the neoplasms cause group, there was a statistically significant increase in the number of deaths 
by 15% mainly because of the addition of malignant neoplasms of skin and bladder cancer to 
the EUROSTAT's list and the shortness of the upper age limit of leukaemia. Finally, the stan-
dardised death rates for the surgical, congenital and perinatal conditions increased significantly 
under the EUROSTAT's list by 69.1 and 59%, respectively, mainly due to the inclusion of some 
surgical conditions (acute abdomen, appendicitis, intestinal obstruction, etc.) and the extension 
of the scope of congenital malformations to the overall 17 chapters of ICD‐10.
5. Discussion about conceptual problems
While avoidable mortality seems to be an innovative indicator for measuring the effectiveness 
of medical services, it has number of limitations resulting from the data sets relevance, as well 
as the concept itself. It is very important to clearly distinguish between the meaning of the 
avoidable, amenable and preventable mortality. These terms are often mixed up what lead to 
the confusion in their interpretation. For example, interpreting the decrease in avoidable mor-
tality only such as observing a positive impact of treatment can mask an effective introduction 
of public health interventions.
Since health care system characteristics as well as their levels of accessibility vary from coun-
try to country, there is an absence of international agreement on the uniform selection of 
causes of death and age limit in the cross‐country comparison. Although the methodologies 
strictly do not distinguish causes of death or age limits for men and women separately, it 
would be useful to further develop the concept of avoidable mortality differentiating age 
limits for males and females to reflect the greater longevity of women. In our complemen-
tary analyses [29, 30], we found that amenable mortality is generally higher in men than in 
women, irrespective of the four concept used. The differences between men and women are 
much higher in countries with higher amenable mortality than in countries with lower ame-
nable death rates. These facts are consistent with the findings of a research project AMIEHS. 
It declares that the disparity between male and female premature mortality is partially deter-
mined by the provision of health care.
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This concept does not take into account the fact that different countries do not have the same 
health care resources needed for effective treatment, such as available new required technolo-
gies, medical skills or sufficient number of professionals. Additionally, it is not monitored 
whether countries secure distribution and dissemination of the necessary resources. For this 
reason, avoidable mortality should be interpreted in the context of many other available charac-
teristics of health care system performance in the country. Hence, avoidable mortality can be an 
effective indicator in the assessment of progress achieved by the country in a certain time period.
The lack of resources can lead to the increase of disease prevalence that is not adjusted in the 
amenable mortality indicator. For example, based on our previous study [31], Slovakia has 
gained the worst values of standardised mortality rate of ischaemic heart disease (above 500 
deaths per 100,000) across the European countries in the long term. In this case, we should 
find out whether incidence or prevalence of ischaemic heart disease was not significantly 
increased in the examined time period, otherwise, we might interpret mistakenly a decrease 
of the quality of health care by an ineffective treatment of ischaemic heart disease or preven-
tion programs in Slovakia. It is useful to assess the individual diagnosis in the given countries, 
as the countries with high levels of avoidable mortality tend to have a high level of mortality 
in individual cases.
Additionally, we see a disadvantage of variations in diagnostic practices and cause of death 
coding between countries, what also impacts both on international comparison and national 
level assessment of amenable mortality. We found out that by 2009, causes of death were coded 
at the third digit level (e.g. B17), while since 2010 at the fourth digit level (e.g. B171). These dis-
crepancies may have led to the distortion of comparison of causes of death over time. The use 
of EUROSTAT's list before 2010 could overvalue the number of deaths, since the whole group 
of ‘other acute viral hepatitis’ (B17) would have been considered instead of ‘hepatitis C’ (B171).
One of the reasons for the benefits of composing the avoidable mortality concept at the national 
level, supported by previous studies of AMIEHS and Office for National Statistics, may be a 
time lag between the improved of health care services or introduction of a public health pre-
vention program and a corresponding decrease of amenable mortality. Based on AMIEHS, a 
time lag was 7 years, while the Office for National Statistics in England suggests that selection 
of avoidable causes of death should be updated every 3 years.
We have to realise that variations in avoidable mortality are also influenced by socio‐eco-
nomic factors, which can mask the impact of health care system effectiveness. We consider as 
the main limitation of the concept of avoidable mortality the fact that many factors beyond 
the health system influence mortality and an indicator of avoidable mortality does not cap-
ture many of them. Therefore, cross‐country comparison based only on this indicator can be 
biased. Other complementary indicators such as health services supply, health expenditures 
or gains in quality of life should be used in combination with avoidable mortality indicators 
to assess the effectiveness of the health care system.
Permanent evaluation of the concept based on the epidemiological studies, availability of 
health technologies and interventions supported by empirical evidence could help create an 
effective tool for measurement avoidable mortality mainly at the national level.
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6. Conclusion
The aim of this study is to compare the impact of the four latest lists of causes of death on the 
age‐standardised amenable death rates across the European Union countries in 2014. Our results 
showed that the rank order of countries does not change significantly, even though we applied 
Nolte and McKee, Tobias and Yeh, AMIEHS or EUROSTAT's concepts. In addition, we analysed 
whether age‐standardised rates of amenable mortality based on AMIEHS or EUROSTAT's list 
are significantly different by sex and causes of death in Slovakia. We revealed that amenable 
mortality rates calculated by sex under the EUROSTAT's list were significantly higher than to 
the rates under the AMIEHS's list. This finding suggests that the structure of diseases together 
with the given age limits significantly influence the value of standardised amenable death rates, 
and hence, it is beneficial to develop the concept of amenable mortality at the national level in 
the light of actual availability of medical skills and effective treatments in the country.
Our results can serve as a valuable platform for revising the ‘Strategic framework of health 
system in the Slovak Republic’ aimed at increasing effectiveness of the health care system. 
Accurate quantification of the impacts of morbidity, comorbidities, socio‐economic factors, 
lifestyle, health behaviours and others factors provide an extensive support in the interpreta-
tion of the development of avoidable mortality not only in international comparisons, but also 
in the development Slovak’s own avoidable mortality methodology.
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